Cargando…

Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft‐tissue sarcoma

Olaratumab, a monoclonal antibody targeting human platelet‐derived growth factor receptor α, plus doxorubicin significantly improved overall survival in patients with advanced soft‐tissue sarcoma (STS) in a prior phase 1b/2 randomized trial. Subsequent exposure‐response analysis suggested that highe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yonemori, Kan, Kodaira, Makoto, Satoh, Taroh, Kudo, Toshihiro, Takahashi, Shunji, Nakano, Kenji, Ando, Yuichi, Shimokata, Tomoya, Mori, Joji, Inoue, Koichi, Oakley, Gerard J., Sakaguchi, Sachi, Tamura, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272083/ https://www.ncbi.nlm.nih.gov/pubmed/30353601 http://dx.doi.org/10.1111/cas.13846

Ejemplares similares

Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States
por: Zuluaga-Sanchez, Santiago, et al.
Publicado: (2018)

Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland
por: Gennatas, Spyridon, et al.
Publicado: (2020)

Olaratumab’s failure in soft tissue sarcoma
por: Bou Zerdan, Maroun, et al.
Publicado: (2021)

Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience
por: Striefler, Jana Käthe, et al.
Publicado: (2020)

Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma
por: Jones, Robin L., et al.
Publicado: (2018)

Developments in the management of advanced soft-tissue sarcoma – olaratumab in context
por: Moroncini, Gianluca, et al.
Publicado: (2018)

Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma
por: Villalobos, Victor M., et al.
Publicado: (2019)

Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas
por: Attia, Steven, et al.
Publicado: (2023)

Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma
por: Moore, Donald C., et al.
Publicado: (2018)

Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy
por: Davis, Elizabeth J, et al.
Publicado: (2017)

EXTRAVASATION OF PEGYLATED-LIPOSOMAL DOXORUBICIN: FAVORABLE OUTCOME AFTER IMMEDIATE SUBCUTANEOUS ADMINISTRATION OF CORTICOSTEROIDS
por: MITSUMA, AYAKO, et al.
Publicado: (2012)

Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study
por: Kudo, Toshihiro, et al.
Publicado: (2020)

Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor‐positive advanced breast cancer
por: Tamura, Kenji, et al.
Publicado: (2018)

Translocation-Related Sarcomas
por: Nakano, Kenji, et al.
Publicado: (2018)

Incidence and Management of Olaratumab Infusion-Related Reactions
por: Van Tine, Brian A., et al.
Publicado: (2019)

Precision Medicine in Soft Tissue Sarcoma Treatment
por: Nakano, Kenji, et al.
Publicado: (2020)

Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma
por: Pender, Alexandra, et al.
Publicado: (2017)

Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas
por: Nakano, Kenji, et al.
Publicado: (2018)

The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model
por: Higuchi, Takashi, et al.
Publicado: (2019)

Outcome for Advanced or Metastatic Soft Tissue Sarcoma of Nonextremities Treated with Doxorubicin-Based Chemotherapy: A Retrospective Study from a Single Cancer Institution
por: Marshall, Shoko, et al.
Publicado: (2018)

Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma
por: Ueda, Takafumi, et al.
Publicado: (2014)

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
por: Kawai, Akira, et al.
Publicado: (2017)

Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site
por: Kodaira, Makoto, et al.
Publicado: (2018)

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
por: McGuire, William P., et al.
Publicado: (2018)

Phase I study of olaratumab in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2014)

Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?
por: Kyriazoglou, Anastasios, et al.
Publicado: (2019)

Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts
por: Cornillie, Jasmien, et al.
Publicado: (2019)

Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?
por: Kyriazoglou, Anastasios, et al.
Publicado: (2020)

Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
por: Schöffski, Patrick, et al.
Publicado: (2023)

Content Analysis of Oncology-Related Pharmaceutical Advertising in a Peer-Reviewed Medical Journal
por: Yonemori, Kan, et al.
Publicado: (2012)

CARBOPLATIN DOSING FOR ADULT JAPANESE PATIENTS
por: ANDO, YUICHI, et al.
Publicado: (2014)

Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2015)

The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site
por: Sato, Jun, et al.
Publicado: (2019)

Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer
por: Takano, Yuko, et al.
Publicado: (2021)

A rapid and durable response to larotrectinib in a patient with NTRK fusion-positive secretory carcinoma originating from the external auditory canal
por: Ando, Yuichi, et al.
Publicado: (2022)

Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours
por: Yonemori, Kan, et al.
Publicado: (2016)

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
por: Iizumi, Sakura, et al.
Publicado: (2017)

Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy
por: Iwasa, Satoru, et al.
Publicado: (2020)

Challenges of Systemic Therapy Investigations for Bone Sarcomas
por: Nakano, Kenji
Publicado: (2022)

A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer
por: Takahashi, Shunji, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2uf25g1fmukkoc6d9hcealoj4j